Close Menu

drug screening

The Seattle-based firm will use the funding to improve AI integration and further develop its Paris 3D tumor organoid diagnostic and drug discovery platform.

The researchers created a resource of cancer dependencies and developed a framework to prioritize existing cancer drug targets and suggest new ones.

They further found that cancers with inactivating mutations in MARK3 and other kinases are susceptible to alkylating chemotherapeutic agents.

The Israeli biotechnology firm hopes that a successful outcome of the study with Centre Léon-Bérard will raise its profile among oncologists.

Using genomic data from large cancer cell line collections, investigators identified versions of spliced genes that spell better or worse drug response.

Investigators developed a pooled method for simultaneously sequencing RNA in bulk sets of samples being profiled by high-throughput screening assays.

The company combines screening of live, patient-derived tumor cells with DNA sequencing and data analysis to match individuals with optimal drug therapies.

The assay combines high-throughput drug screening of live, patient-derived tumor cells with DNA sequencing and data analysis to match patients with drug therapies.

Researchers screened cancer cell lines to detect mutations and drug combinations that might sensitize tumors to drugs that impair anti-apoptosis proteins.

Agilent and CRO PureHoney will develop new applications for the RapidFire 365 system, including workflows for pharmaceutical research, forensics, and metabolomics.

Pages

Russian CRISPR researcher moves along with plans to ultimately alter the genes of embryos of deaf couples, though awaits regulatory approval, Nature News reports.

University of California, San Francisco, researchers have uncovered a gene mutations that appears to make a father-son duo more efficient sleepers.

NPR reports a large health insurer has begun to cover some pharmacogenetic tests for psychiatric drugs.

In PLOS this week: genome-wide association study of non-syndromic orofacial cleft subtypes, epigenetic and transcriptomic analysis of pancreatic ductal adenocarcinoma, and more.